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A review was undertaken of all patients treated at Royal Adelaide Hospital, South Australia with total body irradiation (TBI) for the
purpose of assessing the incidence of interstitial pneumonitis (IP) and possible prognostic factors for its development. The aim was
also to assess the impact of IP and other prognostic factors on long-term survival outcome following bone marrow transplantation. A
total of 84 patients received TBI, with 12Gy in six fractions delivered using two different instantaneous dose rates of 7.5 and
15cGymin
 1. This series included 26 cases of acute lymphoblastic leukaemia, 26 of multiple myeloma and 15 of acute myelogenous
leukaemia. On multivariate analysis, a higher dose rate was independently significant for an increased risk of IP.
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Total body irradiation (TBI) is frequently used for conditioning
prior to allogeneic bone marrow transplantation (BMT) due to its
immunosuppressive effect on the host immune system, thus
minimising the risk of engraftment failure (Torres et al, 1982;
Cardozo et al, 1985; Kader et al, 1994). This role has been used
principally in acute myelogenous leukaemia (AML) and acute
lymphoblastic leukaemia (ALL). In addition to aiding engraftment,
TBI provides additional malignant cell kill and is active in
chemotherapy inaccessible sanctuary sites. These latter functions
are the predominant rationale for the use of TBI in autologous
transplantation. Randomised studies of BMT for AML with and
without TBI as part of the conditioning regimen have found that
TBI regimens provide equivalent or better outcomes for survival
(Blaise et al, 1992; Blume et al, 1993; Dusenbery et al, 1995;
Hartman et al, 1998). Pulmonary complications are a significant
source of morbidity and mortality with BMT for haematological
malignancies (Tait et al, 1991). Interstitial pneumonitis (IP) has a
documented incidence ranging from 10 to 84% (Weiner et al,
1986). The development of IP is increased by various risk factors
including infection, particular types of chemotherapy, the use of
single fraction TBI at higher dose rates (Bortin et al, 1982; Deeg,
1983), higher total TBI lung dose (Keane et al, 1981; Torres et al,
1982), methotrexate administration post-transplant (Bortin et al,
1982; Weiner et al, 1986) and acute graft-versus-host disease
(GVHD) (Torres et al, 1982; Cardozo et al, 1985; Weiner et al,
1986; Latini et al, 1992; Ozsahin et al, 1992, 1994). The relative
contributions of each are difficult to establish. The mortality rate
with IP has been reported as high as 80% (Gogna et al, 1992).
MATERIALS AND METHODS
A review of all patients treated with TBI at Royal Adelaide
Hospital, South Australia revealed a total of 95 patients. Prior to
1982, nine patients were treated with a single dose of 7–8.5Gy, at
15cGymin
 1 prescribed to the mid-pelvis. From 1982 to February
1991, 55 patients received fractionated TBI, with 53 receiving 12Gy
in six fractions over 3 days, with a minimum interfraction interval
of 6h, at an instantaneous dose rate of 15cGymin
 1. Two
paediatric patients were prescribed fractionated doses of 9 and
8.5Gy, respectively. From March 1991, the dose rate was reduced
to 7.5cGymin
 1, with 31 patients receiving 12Gy in six fractions at
this dose rate (Table 1). In order to produce a more homogeneous
study population for the purposes of analysis, only those patients
who received 12Gy in six fractions were included, thus excluding
nine single dose patients and two lower dose patients. This resulted
in 53 patients at 15cGymin
 1 dose rate and 31 at 7.5cGymin
 1
(total of 84 patients).
The age range of the patients was 4–66 years with a male/female
ratio of 1.7:1. Primary diagnoses consisted of 26 cases of ALL, 26
of multiple myeloma (MM), 15 of AML, 10 of non-Hodgkin’s
lymphoma (NHL), and a miscellaneous group including chronic
myelogenous leukaemia and Ewing’s sarcoma (Table 1). Initial
chemotherapeutic management was according to the prevailing
best practice guidelines. Many of the cases were enrolled in
international and national clinical trials including TBI and BMT.
A number of cases were, however, transplanted in relapse or with
advanced disease under less than clinically optimal conditions.
In vivo dosimetry of prescribed dose was obtained using diode
measurements and limited thermoluminescent dosimetry (TLD)
measurements prior to 1987 and TLDs at six anatomical sites per
patient thereafter (Van Dam and Marinello, 1994). The point of
prescribed dose altered over the period of this review, with the
dose being prescribed to mid-pelvis between 1982 and 1987. In
1988, computerised tomography (CT)-based computer planning
with full lung corrections was implemented, with the point of dose
prescription thereafter being the maximum lung dose. For the
15cGymin
 1 group, 41 patients (77%) were prescribed to mid-
pelvis, 12 (23%) to the maximum lung dose point and all patients
in the 7.5cGymin
 1 group to the maximum lung dose point. In
vivo lateral chest wall TLD readings were used to estimate the
mean thoracic dose at the level of the second intercostal space.
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lComparison of readings (n¼122) for the two prescription
methods (mid-pelvis and maximum lung dose point) was
performed. All patients had in vivo TLD dosimetry during the
initial fraction of TBI. In some patients TLDs were repeated during
the second fraction for quality assurance purposes. The in vivo
TLD readings showed a wide range of doses (1.72–2.01Gy for the
mid-pelvis prescription cases, and 1.55–2.26Gy for the CT
planned cases). The mean values were 1.88 and 1.81Gy,
respectively, a difference of 0.07Gy per 2Gy fraction. A ‘t’-test
comparison of the TLD readings for the two prescription point
methods did not show any significant difference with a ‘P’-value of
0.86 (95% confidence interval – 0.72, 0.86).
All patients were treated with 10 megavoltage (MV) photons
with parallel opposed lateral fields at an extended focus to skin
distance of 4m. All patients had chest wall bolus applied for soft-
tissue homogeneity and to reduce lung dosage. Lead attenuators
were used as needed to compensate for reduced separation in the
region of the head and neck, and lower limbs from the mid-thigh
down. These attenuators were adjusted in thickness after TLDs
when indicated, prior to the third fraction of TBI, to maintain a
dose homogeneity within 10% of the prescribed dose. A flat supine
position was used for the single fraction patients, with the
treatment position changed to a semirecumbent supine one at
the time of introduction of fractionated TBI. A 1cm thick perspex
screen adjacent to the treatment couch was used as a beam spoiler
to maintain dose to superficial tissues.
Chemotherapy conditioning prior to TBI was generally with
high-dose cyclophosphamide (80 of 84 cases). Transplant type
following TBI was autologous in 47 cases, allogeneic in 35 and
syngeneic in 2. Histocompatibility locus antigen matching was
identical in 29 of the 35 cases for allogeneic transplantation.
Interstitial pneumonitis was defined as a clinical condition of
dyspnoea and hypoxia with bilateral interstitial opacities on
chest radiographs (Weiner et al, 1986). Infective IP was
diagnosed on lung biopsy, sputum culture or serological
testing. Histological confirmation (lung biopsy or autopsy)
of the clinical diagnosis of IP was possible in only 10 of the 27
cases that developed IP. Acute GVHD was graded 1–4 using
standard criteria of severity of organ involvement (Thomas et al,
1975). Grades 1–2 included cases with mild-to-moderate skin
changes, no or mild gastrointestinal involvement and no or mild
decrease in clinical performance, while grades 3–4 had more
significant changes.
Statistical methods
Survival curves were produced using the Kaplan–Meier method
with log-rank testing. The 95% CIs for survival time and other
study end points are shown within parenthesis. Cox’s regression
analysis was performed to examine the significance of independent
risk factors for survival following TBI. Log binomial regression of
prognostic factors for the development of IP was also performed.
RESULTS
Survival
Survival, with 95% CIs, for the study cohort as a whole is shown in
Figure 1. The overall median survival was 12.5 (7–22) months.
Cox’s regression analysis of survival found IP (hazard ratio
(HR)¼2.37 (1.35, 4.15), P¼0.003) to be independently significant
for decreased survival as illustrated in Figure 2. With respect to
disease type, Cox’s regression analysis found ALL (P¼0.002) and
the miscellaneous group (P¼0.01) had statistically significant
better survival relative to AML, and NHL (P¼0.08) was of
borderline significance relative to AML. Higher dose rate was
significant for poorer survival only on univariate analysis. In all, 14
patients remained alive at the time of analysis, with a total of 116
patient years of observation within this group, and a total of 210
patient years of observation for the entire 84 patients.
Interstitial pneumonitis
Interstitial pneumonitis developed in 27 cases as shown in Table 2,
with infective causes in 10 patients in whom seven cases of
cytomegalovirus were detected. The analysis looked at all cases of
IP regardless of the presence of infection or not (idiopathic IP),
with a median time to onset of IP post-TBI of 30 days (range, 10–
560 days), with two cases beyond 6 months, both idiopathic and
associated with lung GVHD, with one case fatal at 14 months. The
mortality rate for IP was 70% (19 of 27) patients. Acute GVHD
developed in 23 of 35 (66%) allogeneic patients, with grade 1–2 in
15 patients and grade 3–4 in eight patients.
Table 3 shows the univariate log binomial regression analysis of
prognostic risk factors for IP including age, diagnosis, sex,
transplant type, dose rate, GVHD and grade of GVHD. Higher
dose rate and allogeneic transplantation were found to be
significant for a higher risk of IP.
Using log binomial regression, only dose rate was found to be
independently significant for the development of IP, with a dose
rate of 15cGymin
 1 (RR¼3.00 (1.06, 8.43), P¼0.04) significantly
increasing the risk of IP. At 7.5cGymin
 1, there were four of 31
(13%) cases of IP, while at 15cGymin
 1, 23 of 53 (43%) cases were
Table 1 Patient characteristics and treatment
Total patients 84
Sex
Male 53
Female 31
Age range (years) 4–66
Diagnosis
ALL 26
MM 26
AML 15
NHL 10
Other 7
Dose rate
7.5cGymin
 1 31
15cGymin
 1 53
Mid-pelvis 41
Max lung dose pt. 12
Transplant type
Autologous 47
Syngeneic 2
Allogeneic 35
Overall survival following TBI (with 95% confidence interval)
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Figure 1 Overall survival following TBI.
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ldescribed following BMT. In terms of the dose prescription
method, there were 16 of 41 (39%) cases at 15cGymin
 1 to the
mid-pelvis, seven of 12 (58%) cases at 15cGymin
 1 to the
maximum lung dose point, with four of 31 (13%) cases at
7.5cGymin
 1 (all to the maximum lung dose point). The incidence
of idiopathic IP alone with respect to dose rate shows one case only
of 31 (3%) at 7.5cGymin
 1 and 16 of 53 (30%) cases at
15cGymin
 1. The incidence of IP for allogeneic transplantation
was 17 of 35 (49%) cases and for autologous 10 of 49 (20%) cases.
Of 35 allogeneic transplant patients, four (33%) cases of IP were
found among 12 patients without GVHD and 13 (57%) cases
among 23 patients with GVHD.
DISCUSSION
We have found an association between dose rate and risk of IP in
this review of TBI. In previously published data on dose rate and
the risk of IP, a randomised controlled trial of fractionated TBI
assessing the influence of dose rate on the incidence of
pneumonitis found no significant difference for lower range dose
rates of 3 and 6cGymin
 1, with lung shielding limiting the total
lung dose to 9Gy (Ozsahin et al, 1992). Similarly, a retrospective
analysis did not find a dose rate effect comparing dose rates of
2.9–6.5cGymin
 1 with 6.9–8.9cGymin
 1 for fractionated TBI
(Gogna et al, 1992), but again this study used lower dose rates than
in our study. Other publications have stated that with fractionated
doses of 200cGy, dose rate is of little importance for most tissues
since cell death results predominantly from nonrepairable single
hit killing (Peters et al, 1979; Peters, 1980).
In contrast, one univariate analysis found a dose rate
46cGymin
 1 correlated with an increased risk of IP for
fractionated TBI at 2Gy per fraction (Corvo et al, 1999). A large
retrospective review of 932 leukaemic patients who were managed
with allogeneic BMT found a dose rate of less than 6cGymin
 1 was
associated with a decreased incidence of IP, with the dose rate
effect significant for those patients who had received methotrexate
prophylaxis for GVHD (Weiner et al, 1986). Two retrospective
analyses that found decreased incidence rates of IP at dose rates of
o5.8 and 2.5cGymin
 1, respectively, involved patients treated
with a single fraction of TBI where a dose rate effect may be
expected to be present (Bortin et al, 1982; Barrett et al, 1983).
Support for a possible dose rate effect can also be found in
experimental animal data where the lethal dose for 50% mortality
(LD50) from pneumonitis increases with decreasing dose per
fraction below 2Gy per fraction, suggesting normal tissue repair at
doses below 2Gy, and hence increased repair at decreased dose
rates for 2Gy fractions (Parkins et al, 1985).
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Figure 2 Survival and IP status.
Table 2 Interstitial pneumonitis
Total IP (cases) 27
Idiopathic 17
Infective 10
CMV diagnosed 7
Fatal IP 19
Mortality rate 19/27 (70%)
Dose rate
15cGymin
 1 23/53 (43%)
Mid-pelvis 16/41 (39%)
Max lung dose pt 7/12 (58%)
7.5cGymin
 1 4/31 (13%)
IP¼Interstitial pneumonitis.
Table 3 Univariate log binomial regression of risk factors for IP
At risk Developed IP (%) Unadjusted relative risk 95% CI P-value
Age (years) 0.98 (0.97, 1.00) 0.08
Sex
Female 31 12 (39%) 1.00
Male 53 15 (28%) 0.73 (0.39, 1.35) 0.32
Transplant type
Autologous/other 49 10 (20%) 1.00
Allogeneic 35 17 (49%) 2.38 (1.24, 4.56) 0.01
Dose rate
7.5cGy 31 4 (13%) 1.00
15cGy 53 23 (43%) 3.36 (1.28, 8.83) 0.004
GVHD
Absent 12 4 (33%) 1.00
Present 23 13 (57%) 1.70 (0.71, 4.07) 0.19
GVHD
Grades 1–2 15 9 (60%) 1.00
Grades 3–4 8 4 (50%) 0.83 (0.37, 1.87) 0.65
IF¼Interstitial pneumonitis; CI¼confidence interval.
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lThe analysis as in our series of all cases of IP without separation
of infective from idiopathic cases has been performed previously
(Bortin et al, 1982; Weiner et al, 1986; Ozsahin et al, 1992; Girinsky
et al, 1994; Morgan et al, 1996). We have chosen not to analyse
separately as the methods of diagnosing infection are not
equivalent for all the cases, such that a proportion of infective
cases from the earlier years may have been classified erroneously
as idiopathic. Moreover, if it is argued that it is only valid to
analyse idiopathic cases since infective IP may be due to a number
of causes other than TBI, then the crude incidence figures for our
series for idiopathic IP demonstrate a strong dose rate relation-
ship, with only one case of 31 at 7.5cGymin
 1 and 16 of 53 (30%)
cases at 15cGymin
 1.
With respect to transplant type, other authors have demon-
strated a reduced risk of IP with autologous transplantation. One
analysis found the risk of IP to be 27% (27 of 99) with allogeneic
transplantation and 0% (zero of nine) with autologous, but this
was not statistically significant due to low numbers (Morgan et al,
1996), while other literature reports a significantly decreased
incidence of IP after autologous transplantation compared to
similarly treated allogeneic transplant patients (Wingard et al,
1998). We were only able to demonstrate, however, a reduced risk
of IP for autologous transplantation on univariate analysis.
Our study has not found acute GVHD to be an independent
prognostic factor for IP. Previous literature has reported the
absence of GVHD as contributing to a reduced risk of IP (Latini
et al, 1992), and the presence of severe GVHD to be a significant
risk factor for IP and early mortality (Weiner et al, 1986; Valls et al,
1993). Graft-versus-host disease was found on multivariate
analysis of a randomised study to be significant for an increased
risk of IP (Ozsahin et al, 1992), and a similar result was found in an
earlier analysis (Torres et al, 1982). Conversely, two retrospective
studies with mostly fractionated TBI could find no correlation
between acute GVHD and the incidence of IP (Morgan et al, 1996;
Aristei et al, 1998).
Our statistical analysis excluded single fraction patients, but it is
worth noting that on review, six of our nine single dose patients
developed IP. Fractionation as a factor for a reduced risk of IP is
not always consistently reported in the literature, where the single
doses tend to be lower, and hence are associated with an increased
risk of leukaemic recurrence (Girinsky et al, 1994). One early
randomised trial comparing a single dose of 10Gy with
fractionated TBI of 12Gy in six fractions found no significant
difference for the incidence of IP (Thomas et al, 1982). A
nonrandomised study assessed the influence of fractionation on
the incidence of pneumonitis, finding no difference between single
fraction and fractionated treatment (Kim et al, 1990), but this
study used a modified single fraction TBI schedule with a total
dose of only 7.5Gy (Cosset et al, 1994). Other retrospective studies
have shown reduced risks of IP and fatal IP with fractionated TBI
(Socie et al, 1991; Sutton et al, 1993). Hyperfractionated TBI
schedules have found much reduced incidences of IP compared to
single doses and standard fractionated doses (Cosset et al, 1989;
Latini et al, 1992). The common feature of the above reviews of IP
incidence and fractionation is that higher total doses are possible
with fractionation, but the lungs remain the dose-limiting normal
tissue for TBI.
In further considering the significance of dose rate as an
important determinant of outcome following TBI, the possibility
that the lower dose rate was linked in our cases to the benefits of
CT-based planning allowing the lung tolerance bar to be set more
accurately must be acknowledged. Nevertheless, for patients
prescribed to the maximum lung dose point through CT-based
planning, there is a large difference in IP incidence of seven of 12
(58%) and four of 31 (13%) cases for 15 and 7.5cGymin
 1,
respectively. While a small mean difference of 3.5% (0.07Gy) in
dose/fraction, as observed within the wide dose ranges recorded on
TLDs for the two prescription methods groups, was not statistically
significant, there is a potentially slightly higher dose for that
proportion of the 15cGymin
 1 patients prescribed to mid-pelvis.
However, the IP incidence figures show 16 of 41 (39%) IP cases for
15cGymin
 1 to mid-pelvis, and a higher incidence of IP of seven
of 12 (58%) cases for 15cGymin
 1 to the maximum lung dose
point.
Finally, the possibility of other time-dependent improvements in
patient management, as confounding factors, cannot be excluded
in considering the results of our review. Such improvements
include improved bone marrow harvesting and storage, more
efficacious antibiotics post-transplant, greater use of cytokines to
recover pancytopenia and general improvements in clincal
diagnosis and care, all of which may have significantly contributed
to the reduced risk of IP in the latter cohort treated at
7.5cGymin
 1.
In conclusion, this review of TBI conditioning for BMT provides
a more mature long-term analysis of outcomes than other reviews
in the literature. A higher TBI dose rate has been shown to be an
adverse prognostic factor for developing IP, confirming earlier
data from a number of centres (Bortin et al, 1982; Barrett et al,
1983; Weiner et al, 1986; Morgan et al, 1996; Wingard et al, 1998;
Corvo et al, 1999). As long-term survival is possible following BMT
for those who survive the early post-transplant dangers of IP, the
use of fractionated TBI at a dose rate of 7.5cGymin
 1 or less
rather than 15cGymin
 1 is recommended, as a means of reducing
IP and increasing survival in cases where such an option exists.
The importance of high-level quality assurance procedures and
CT-based lung corrected dosimetry for TBI is also emphasised.
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